4569.T Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 09:15):

Stats
Šios dienos apimtis	84 900.00
Vidutinė apimtis	69 440.00
Rinkos kapitalizacija	105.02B
EPS	¥0 ( 2024-02-05 )
Kita pelno data	( ¥0 ) 2024-05-08
Last Dividend	¥32.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	24.63
ATR14	¥1.224 (0.07%)

Tūris Koreliacija

Ilgas: 0.12 (neutral)

Trumpas: 0.91 (very strong)

Signal:(59.072) Expect same movement, but be aware

KYORIN Holdings, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

KYORIN Holdings, Inc. Koreliacija - Valiuta/Žaliavos

0.74
( moderate )

0.86
( strong )

-0.19
( neutral )

0.86
( strong )

-0.21
( neutral )

-0.87
( strong negative )

KYORIN Holdings, Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	¥113.27B
Bruto pelnas:	¥50.17B (44.29 %)
EPS:	¥82.42

FY	2022
Pajamos:	¥113.27B
Bruto pelnas:	¥50.17B (44.29 %)
EPS:	¥82.42

FY	2022
Pajamos:	¥105.53B
Bruto pelnas:	¥49.44B (46.85 %)
EPS:	¥68.62

FY	2021
Pajamos:	¥102.90B
Bruto pelnas:	¥51.63B (50.17 %)
EPS:	¥106.99

Financial Reports:

No articles found.

KYORIN Holdings, Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥20.00 (N/A)	¥0 (N/A)	¥32.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

KYORIN Holdings, Inc. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.34 - Stable (13.14%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥10.00	2006-09-26
Last Dividend	¥32.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	35	--
Total Paid Out	¥862.50	--
Avg. Dividend % Per Year	0.00%	--
Score	3.6	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.34
Div. Directional Score	7.48	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

3.60

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8174.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7552.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6762.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6101.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4812.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
4026.T	Ex Dividend Knight	2023-10-30	Semi-Annually	0.00%
9982.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%
3242.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
8966.T	Ex Dividend Knight	2023-11-29	Semi-Annually	0.00%
2267.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0356	1.500	9.29	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0238	1.200	9.21	10.00	[0 - 0.3]
returnOnEquityTTM	0.0339	1.500	-0.735	-1.102	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.53	0.800	2.34	1.871	[1 - 3]
quickRatioTTM	1.327	0.800	6.90	5.52	[0.8 - 2.5]
cashRatioTTM	0.402	1.500	8.88	10.00	[0.2 - 2]
debtRatioTTM	0.116	-1.500	8.06	-10.00	[0 - 0.6]
interestCoverageTTM	75.14	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.164	-1.500	9.34	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.429	1.000	6.18	6.18	[0.2 - 0.8]
operatingProfitMarginTTM	0.0408	1.000	-1.185	-1.185	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.405	1.000	8.86	8.86	[0.2 - 2]
assetTurnoverTTM	0.670	0.800	8.87	7.10	[0.5 - 2]
Total Score				10.62

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.65	1.000	7.61	0	[1 - 100]
returnOnEquityTTM	0.0339	2.50	-0.472	-1.102	[0.1 - 1.5]
freeCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.84	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	146.46	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.226	1.500	5.16	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0702	1.000	-0.745	0	[0.1 - 0.5]
Total Score				4.34

KYORIN Holdings, Inc.

KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.